Your trusted source for investing success
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of each.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.
By Pia Rivera
HTG Molecular Diagnostics leads the list of last week’s life science gainers on the NASDAQ, followed by La Jolla Pharmaceutical, Dynavax Technologies, NewLink Genetics and BioCryst Pharmaceutical.
By Pia Rivera
Thom Calandra is known to investors in the resource space. Recently, he wrote about biotechnology and started his own index of companies he follows, called Genes, Genes on Motif.
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
By Pia Rivera
Editas Medicine (NASDAQ:EDIT) reported that the US Patent and Trademark Office has issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and the Broad Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the Company exclusively licenses from Broad.
As quoted in
At the close of 2016, the moment finally arrived: cells modified with CRISPR-Cas 9 were injected into a human subject. With more trials set to launch in 2017, it’s worth examining these studies in closer detail.
By Pia Rivera
Here’s a closer look at last week’s top gainers.
What can you expect from genetics stocks in 2017? We touched base with those in the know to bring you some predictions for the year ahead.
